Integrative genomics identifies the molecular basis of resistance to azacitidine therapy in myelodysplastic syndromes

Integrative genomics identifies the molecular basis of resistance to azacitidine therapy in myelodysplastic syndromes

Myelodysplastic syndromes and chronic myelomonocytic leukemia are blood disorders characterized by ineffective hematopoiesis and progressive marrow failure that can transform into acute leukemia. The DNA methyltransferase inhibitor 5-azacytidine (AZA) is the most effective pharmacological option, bu...

Πλήρης περιγραφή

Λεπτομέρειες βιβλιογραφικής εγγραφής
Κύριοι συγγραφείς:	Unnikrishnan, A, Deshpande, NP, Verma, A, Kumari, A, Richards, LA, Knezevic, K, Chandrakanthan, V, Thoms, JAI, Tursky, ML, Huang, Y, Ali, Z, Olivier, J, Galbraith, S, Kulasekararaj, AG, Tobiasson, M, Karimi, M, Pellagatti, A, Wilson, SR, Lindeman, R, Young, B, Ramakrishna, R, Arthur, C, Stark, R, Crispin, P, Curnow, J, Warburton, P, Roncolato, F, Boultwood, J, Lynch, K, Jacobsen, SEW, Mufti, GJ, Hellstrom-Lindberg, E, Wilkins, MR, MacKenzie, KL, Wong, JWH, Campbell, PJ, Pimanda, JE
Μορφή:	Journal article
Γλώσσα:	English
Έκδοση:	Cell Press 2017

Παρόμοια τεκμήρια

Myelodysplastic syndromes: moving towards personalized management
ανά: Eva Hellström-Lindberg, κ.ά.
Έκδοση: (2020-07-01)

Spliceosome mutations: 1 plus 1 does not always equal 2
ανά: Pellagatti, A, κ.ά.
Έκδοση: (2020)

Reduced translation of GATA1 in Diamond-Blackfan anemia.
ανά: Boultwood, J, κ.ά.
Έκδοση: (2014)

SF3B1 mutant myelodysplastic syndrome: Recent advances
ανά: Pellagatti, A, κ.ά.
Έκδοση: (2020)

Splicing factor gene mutations in the myelodysplastic syndromes: impact on disease phenotype and therapeutic applications.
ανά: Pellagatti, A, κ.ά.
Έκδοση: (2016)

Clonal heterogeneity in the 5q- syndrome: p53 expressing progenitors prevail during lenalidomide treatment and expand at disease progression.
ανά: Jädersten, M, κ.ά.
Έκδοση: (2009)

Response of high-risk MDS to azacitidine and lenalidomide is impacted by baseline and acquired mutations in a cluster of three inositide-specific genes
ανά: Follo, M, κ.ά.
Έκδοση: (2019)

P557: HEMATOLOGIC IMPROVEMENTS WITH IVOSIDENIB + AZACITIDINE COMPARED WITH PLACEBO + AZACITIDINE IN PATIENTS WITH NEWLY-DIAGNOSED ACUTE MYELOID LEUKEMIA
ανά: H. Dohner, κ.ά.
Έκδοση: (2022-06-01)

Magrolimab + azacitidine versus azacitidine + placebo in untreated higher risk myelodysplastic syndrome: the Phase 3, randomized, ENHANCE Study
ανά: Garcia-Manero, G, κ.ά.
Έκδοση: (2021)

Haploinsufficiency of ribosomal proteins and p53 activation in anemia: Diamond-Blackfan anemia and the 5q- syndrome.
ανά: Boultwood, J, κ.ά.
Έκδοση: (2012)

5q- syndrome.
ανά: Boultwood, J, κ.ά.
Έκδοση: (2012)

A pilot phase I dose finding safety study of the thrombopoietin-receptor agonist, eltrombopag, in patients with myelodysplastic syndrome treated with azacitidine.
ανά: Svensson, T, κ.ά.
Έκδοση: (2014)

P556: CHANGES IN HEALTH-RELATED QUALITY OF LIFE IN PATIENTS WITH NEWLY-DIAGNOSED ACUTE MYELOID LEUKEMIA RECEIVING IVOSIDENIB + AZACITIDINE OR PLACEBO + AZACITIDINE
ανά: A. Schuh, κ.ά.
Έκδοση: (2022-06-01)

Magrolimab + azacitidine versus azacitidine + placebo in untreated higher risk (HR) myelodysplastic syndrome (MDS): the phase 3, randomized, ENHANCE study
ανά: Garcia-Manero, G, κ.ά.
Έκδοση: (2021)

Magrolimab + azacitidine versus azacitidine + placebo in untreated higher risk (HR) myelodysplastic syndromes (MDS): the Phase 3, randomized, ENHANCE Study
ανά: Garcia-Manero, G, κ.ά.
Έκδοση: (2021)

PHASE 2 STUDY OF PEVONEDISTAT + AZACITIDINE VERSUS AZACITIDINE IN PATIENTS WITH HIGHER-RISK MYELODYSPLASTIC SYNDROMES/CHRONIC MYELOMONOCYTIC LEUKEMIA OR LOW-BLAST ACUTE MYELOGENOUS LEUKEMIA (NCT02610777)
ανά: L. Adès, κ.ά.
Έκδοση: (2020-11-01)

P430: MOLECULAR CHARACTERIZATION OF CLINICAL RESPONSE IN NEWLY-DIAGNOSED ACUTE MYELOID LEUKEMIA PATIENTS TREATED WITH IVOSIDENIB + AZACITIDINE COMPARED TO PLACEBO + AZACITIDINE
ανά: S. de Botton, κ.ά.
Έκδοση: (2022-06-01)

Gene expression profiling of day 7 erythroblasts from RARS before and after treatment with G-CSF
ανά: Nikpour, M, κ.ά.
Έκδοση: (2007)

Deregulated Gene Expression Pathways in Myelodysplastic Syndrome Hematopoietic Stem Cells
ανά: Pellagatti, A, κ.ά.
Έκδοση: (2009)

Azacitidine for the treatment of myelodysplastic syndrome, chronic myelomonocytic leukaemia and acute myeloid leukaemia
ανά: R Edlin, κ.ά.
Έκδοση: (2010-05-01)

Azacitidine for the treatment of myelodysplastic syndrome, chronic myelomonocytic leukaemia and acute myeloid leukaemia
ανά: R Edlin, κ.ά.
Έκδοση: (2010-05-01)

P748: SINGLE CELL GENOTYPING OF MATCHED BONE MARROW AND PERIPHERAL BLOOD CELLS IN TREATMENT NAIVE AND AZA-TREATED MDS AND CMML
ανά: A. Schnegg-Kaufmann, κ.ά.
Έκδοση: (2022-06-01)

MDS-197: Magrolimab + azacitidine versus azacitidine + placebo in untreated higher-risk (HR) myelodysplastic syndromes (MDS): the phase 3, randomized, ENHANCE study
ανά: Garcia-Manero, G, κ.ά.
Έκδοση: (2021)

Haploinsufficiency of RPS14 in 5q- syndrome is associated with deregulation of ribosomal- and translation-related genes (British Journal of Haematology (2008) 142, (57-64))
ανά: Pellagatti, A, κ.ά.
Έκδοση: (2009)

Marked down-regulation of nucleophosmin-1 is associated with advanced del(5q) myelodysplastic syndrome.
ανά: Pellagatti, A, κ.ά.
Έκδοση: (2011)

Identification of Prognostic Markers by Gene Expression Profiling In Myelodysplastic Syndrome Hematopoietic Stem Cells
ανά: Pellagatti, A, κ.ά.
Έκδοση: (2010)

Haploinsufficiency of RPS14 in 5q- syndrome is associated with deregulation of ribosomal- and translation-related genes.
ανά: Pellagatti, A, κ.ά.
Έκδοση: (2008)

Marked down-regulation of nucleophosmin-1 is associated with advanced del(5q) myelodysplastic syndrome
ανά: Pellagatti, A, κ.ά.
Έκδοση: (2011)

Del(5q) Myelodysplastic Stem Cells Exhibit Their Clonal Advantage Via Increased Adhesion to the Microenvironment
ανά: Scharenberg, C, κ.ά.
Έκδοση: (2011)

Gene expression profiling in the myelodysplastic syndromes.
ανά: Pellagatti, A, κ.ά.
Έκδοση: (2005)

A miRNA screening identifies miR-192-5p as associated with response to azacitidine and lenalidomide therapy in myelodysplastic syndromes
ανά: Sara Mongiorgi, κ.ά.
Έκδοση: (2023-02-01)

Splicing factor mutations in the myelodysplastic syndromes: target genes and therapeutic approaches
ανά: Armstrong, R, κ.ά.
Έκδοση: (2017)

Advances in the 5q- syndrome.
ανά: Boultwood, J, κ.ά.
Έκδοση: (2010)

Deregulated gene expression pathways in myelodysplastic syndrome hematopoietic stem cells.
ανά: Pellagatti, A, κ.ά.
Έκδοση: (2010)

The AGILE trial of ivosidenib plus azacitidine versus azacitidine alone: How many limitations is too many?
ανά: Anjali Bhatt, κ.ά.
Έκδοση: (2022-11-01)

A Novel Regimen for Treating Melanoma: MCL1 Inhibitors and Azacitidine
ανά: Chiara R. Dart, κ.ά.
Έκδοση: (2021-07-01)

NEW INSIGHTS INTO THE BIOLOGY OF REFRACTORY ANEMIA WITH RING SIDEROBLASTS (RARS) AND IDENTIFICATION OF ERYTHROID G-CSF TARGETS BY GENE EXPRESSION PROFILING
ανά: Nikpour, M, κ.ά.
Έκδοση: (2009)

YI1 Gene expression profiling of day 7 erythroblasts from refractory anemia with ringed sideroblasts (RARS) and microarray-based identification of erythroid granulocyte-CSF (G-CSF) targets
ανά: Nikpour, M, κ.ά.
Έκδοση: (2009)

Gene expression profiling of day 7 erythroblasts from refractory anemia with ringed sideroblasts (RARS) and microarray-based identification of erythroid granulocyte-CSF (G-CSF) targets
ανά: Nikpour, M, κ.ά.
Έκδοση: (2009)

Gene expression profiling of erythroblasts from refractory anaemia with ring sideroblasts (RARS) and effects of G-CSF.
ανά: Nikpour, M, κ.ά.
Έκδοση: (2010)